急性呼吸窘迫综合征
医学
肺
炎症
败血症
急性呼吸窘迫
自噬
转录组
药理学
结扎
弥漫性肺泡损伤
呼吸系统
免疫学
氧化应激
细胞因子
生物信息学
信号转导
呼吸窘迫
全身炎症
治疗效果
细胞激素风暴
药品
全身炎症反应综合征
肺炎
作者
Huaiyu Chen,Shaowu He,Lili Chen,Yu Zhang,Xiaoyan Guo,Yijun Lin,Xinsheng Ren,Wei Li,M Lin,Zhiqing Shen
标识
DOI:10.1186/s12967-026-08431-4
摘要
BACKGROUND: Sepsis-induced acute respiratory distress syndrome (ARDS) is a life-threatening inflammatory lung condition with high mortality and no specific pharmacological treatments. The complex spatial heterogeneity of the lung during sepsis hinders the discovery of effective therapies. This study aimed to use spatial transcriptomics to map the septic lung's molecular landscape to identify and validate a novel therapeutic agent. METHODS: We performed spatial transcriptomics on lung tissues from mice subjected to cecal ligation and puncture (CLP) to model sepsis. A computational drug screen identified Mavacamten. In vitro, lipopolysaccharide-stimulated murine alveolar epithelial cells were used to assess Mavacamten's effects on inflammation and cell injury. In vivo, CLP mice received Mavacamten, and we assessed survival, lung function, pulmonary edema, histology, and inflammatory markers. The underlying mechanism was investigated by analyzing the PI3K/AKT/mTOR pathway and autophagy markers. Statistical analyses included ANOVA, t-tests, and Kaplan-Meier analysis. RESULTS: Spatial transcriptomics revealed distinct cellular clusters that were dramatically rearranged during sepsis. In vitro, Mavacamten significantly attenuated lipopolysaccharide-induced inflammation, cellular injury, and oxidative stress. In the CLP mouse model, Mavacamten treatment markedly improved 7-day survival, restored arterial oxygenation, reduced pulmonary edema, and lessened histological lung injury. Mavacamten also significantly lowered local and systemic pro-inflammatory cytokine levels. Mechanistically, Mavacamten reversed the sepsis-induced inhibition of autophagy and suppressed the activation of the PI3K/AKT/mTOR signaling pathway in lung tissues. CONCLUSIONS: Mavacamten confers robust protection against sepsis-induced ARDS in a preclinical model by mitigating inflammation and lung injury, leading to improved survival. Its therapeutic action is mediated by inhibiting the PI3K/AKT pathway and restoring protective autophagy. Mavacamten is a promising candidate for repurposing in the treatment of sepsis-induced ARDS.
科研通智能强力驱动
Strongly Powered by AbleSci AI